IMBRUVICA® Leukemia Drug Shows Promise For High-Risk Patients

February 17, 2015 6:09 PM

15 0

A new drug from Pharmacyclics, Inc. shows promise in treating high-risk patients suffering from leukemia.

The drug, dubbed IMBRUVICA® (ibrutinib), was reported to be associated with an 88 percent overall response rate with a median study time of 23.2 months in 16 patients with relapsed/refractory (R/R) high-risk chronic lymphocytic leukemia (CLL), a news release reported.

Also read: Groups partner to increase lagging US orchestra diversity

Read more

To category page